Huntington National Bank
CORT icon

Huntington National Bank’s Corcept Therapeutics CORT Stock Holding History

Huntington National Bank’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.56K Buy
110
+51
+86% +$3.08K ﹤0.01% 2043
2026
Q1 		$2.38K Sell
59
-415
-88% -$15.5K ﹤0.01% 2245
2025
Q4 		$16.5K Buy
474
+19
+4% +$1.49K ﹤0.01% 1646
2025
Q3 		$37.8K Sell
455
-24
-5% -$1.74K ﹤0.01% 1371
2025
Q2 		$35.2K Buy
479
+168
+54% +$12.2K ﹤0.01% 1365
2025
Q1 		$35.5K Buy
311
+282
+972% +$17.2K ﹤0.01% 1326
2024
Q4 		$1.46K Hold
29
– – ﹤0.01% 2318
2024
Q3 		$1.34K Hold
29
– – ﹤0.01% 2334
2024
Q2 		$942 Buy
29
+18
+164% +$493 ﹤0.01% 2315
2024
Q1 		$277 Sell
11
-54
-83% -$1.28K ﹤0.01% 2410
2023
Q4 		$2.11K Sell
65
-14
-18% -$384 ﹤0.01% 2063
2023
Q3 		$2.15K Buy
79
+78
+7,800% +$2.26K ﹤0.01% 2034
2023
Q2 		$22 Hold
1
– – ﹤0.01% 3097
2023
Q1 		$22 Hold
1
– – ﹤0.01% 2945
2022
Q4 		$20 Hold
1
– – ﹤0.01% 2855
2022
Q3 		$0 Hold
1
– – ﹤0.01% 2070
2022
Q2 		$0 Hold
1
– – ﹤0.01% 2100
2022
Q1 		$0 Hold
1
– – ﹤0.01% 2087
2021
Q4 		$0 Buy
+1
New +$20 ﹤0.01% 2057
2020
Q2 		– Sell
-529
Closed -$6K – 1528
2020
Q1 		$6K Buy
+529
New +$6.55K ﹤0.01% 1297
2019
Q1 		– Sell
-2,071
Closed -$28K – 1583
2018
Q4 		$28K Sell
2,071
-136
-6% -$1.8K ﹤0.01% 1031
2018
Q3 		$31K Sell
2,207
-174
-7% -$2.43K ﹤0.01% 1110
2018
Q2 		$37K Buy
2,381
+418
+21% +$7.27K ﹤0.01% 1052
2018
Q1 		$32K Buy
+1,963
New +$36.4K ﹤0.01% 1093

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Ingalls & Snyder LLC
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Parallel Advisors
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Huntington National Bank's CORT Position: Q2 2026 in Review

Huntington National Bank increased its Corcept Therapeutics (CORT) stake by 86% in Q2 2026, buying an estimated $3.08K and bringing the position to 110 shares worth $9.56K. The position accounts for ﹤0.01% of the portfolio, ranked #2043.

Huntington National Bank first reported a position in CORT in Q1 2018 and has held it in 24 quarters since. The position peaked at $37.8K in Q3 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Huntington National Bank held 110 shares of Corcept Therapeutics worth $9.56K as of Q2 2026.
  • Huntington National Bank bought 51 Corcept Therapeutics shares in Q2 2026, an estimated $3.08K.
  • Corcept Therapeutics made up ﹤0.01% of Huntington National Bank's portfolio in Q2 2026, its #2043 holding.
  • Huntington National Bank first reported a position in Corcept Therapeutics in Q1 2018 and has held it in 24 quarters since.
  • Huntington National Bank's Corcept Therapeutics position peaked at $37.8K in Q3 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Huntington National Bank's 13F filing for Q2 2026, filed 13 Aug 2026.